AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00815932 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TDCS/sham procedure on five consecutive days
Description: The latency and amplitude of P300, subjective pain intensity, and pain thresholds for tactile and thermal stimuli will be determined at before and 15 min and 120 min after the 1st and 5th tDCS/sham procedure, To receive tDCS/sham treatment, two electrodes will be placed on the patient´s skull (for details see section Methods) and the patient will rest for 5 min. After that, the patient will receive 20 minutes of 2 mA tDCS/sham. Subjective pain intensity, and pain thresholds for tactile and thermal stimuli will be determined before-, 15 min after and 120 min after each tDCS/Sham procedure. At the 1st and 5th tDCS/Sham session, the latency and amplitude of P300 will be determined before-, 15 min after and 120 min after the tDCS/sham procedure.
Study NCT03717610 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: radical surgery with HIPEC
Description: Straight after macroscopic radical cytoreductive surgery, an intraperitoneal hyperthermic perfusion using the open-abdomen technique will be performed with a single dose of cisplatin 100 mg/m2 administered for 90 minutes in the hyperthermic phase (41°C-43°C).
Study NCT04116346 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Oral intake allowed
Description: Oral intake (food and fluids) allowed up to the time of the procedure
Study NCT03715595 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: SSDM group
Description: The patients can perform self-evaluation, including DAS28, morning stiffness duration (MSD) and HAQ, and input medical records (including medication and laboratory test results) every month.
Study NCT03974984 — intervention group
Intervention type: PROCEDURE
Intervention: Colon Resection
Description: All patients undergo laparoscopic colon cancer resection.
Study NCT03974984 — intervention group
Intervention type: PROCEDURE
Intervention: Epidural anesthesia
Description: Epidural inserted preoperatively and kept for 1 day postoperatively
Study NCT03974984 — intervention group
Intervention type: DRUG
Intervention: NSAID
Description: NSAID administered according to standard operating procedure postoperatively
Study NCT02700802 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Feed1st
Description: Feed1st is a unique hospital-based hunger mitigation program that, since 2010, has operated low-cost, self-serve food pantries at Comer Children's Hospital. All parents and caregivers with a hospitalized child have 24/7 free access to these self-serve pantries with the option to eat food in the pantry, carry out as much food as needed, and contribute back to the pantry with food, volunteerism, or other resources. The program also offers free phone/text/email navigation for food support and other basic needs resources. We aim to conduct a 3-arm, randomized comparative effectiveness study to evaluate the impact, versus usual care, of two alternative referral strategies to increase Feed1st program utilization and impact.
Study NCT02649231 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketamine
Description: 0.8 mg/kg ketamine
Study NCT02649231 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine
Description: 0.8 mg/kg ketamine
Study NCT02649231 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 0.9% saline
Study NCT02649231 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: 0.9% saline
Study NCT02649231 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Psychological Therapy
Description: Manualised relapse prevention based CBT
Study NCT02649231 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Psychological Therapy
Description: Manualised relapse prevention based CBT
Study NCT02649231 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Alcohol Education
Description: Simple education about alcohol effects
Study NCT02649231 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Alcohol Education
Description: Simple education about alcohol effects
Study NCT03295799 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Patient Self-Management
Description: Patient will manage their own warfarin therapy.
Study NCT04022057 — intervention group
Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Ropivacaine injection
Description: Local anesthetic injection
Study NCT03111888 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Silicone Stent Airway Implant
Description: The Patient-Specific Tracheobronchial Stent is a silicone stent indicated for use in adults that have stenosis of the airway. The subject device takes a CT scan, thresholds out the airway from the other anatomy, and allows the physician to digitally build the stent to his/her desired dimensions. According to the physician's design, a patient-specific stent can be manufactured using rapid prototyping technology. The patient-specific stent is indicated for use with any rigid bronchoscopy/stent application system that fits the design envelope.
Study NCT03170505 — intervention group
Intervention type: PROCEDURE
Intervention: repairing fistula
Description: A tailored piece of Acellular Dermal Matrix or Conchal Cartilage will be placed between the oral and nasal layers for repair of a Cleft Palate.
Study NCT04249206 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Root Canal Treatment
Study NCT04249206 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Root Canal Treatment
Study NCT02046785 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: 0.9% saline solution
Description: comparing values obtained before and after administration of 500 ml of 0.9% salin
Study NCT03629847 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolimus
Description: Drug: Everolimus will be administrated in combination with the intravenous radiolabelled Lu-177 DOTATATE therapy.
Study NCT02427373 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: fish oil ethyl ester
Study NCT02427373 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: fish oil triglyceride
Study NCT02427373 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: krill oil
Study NCT03339791 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Sleeve Gastrectomy
Description: Laparoscopic Sleeve Gastrectomy. Technique: complete mobilization of the greater curvature and gastric fundus up to the angle of Hiss; stapling beginning at 3 to 4 cm away from the pylorus; bougie size 32 French; oversuture of the staple line; hiatoplasty in selected cases; routine drainage of the abdominal cavity
Study NCT03339791 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Gastric Bypass
Description: Laparoscopic Gastric Bypass. Technique: Pouch size 30 to 40 ml, biliopancreatic limb 70 to 100 cm, alimentary limb 100 to 120 cm, antecolic, routine closure of the mesenterial defects, routine drainage of the abdominal cavity
Study NCT02552381 — intervention group
Intervention type: OTHER
Intervention: Fibrin Structure
Description: Modifications of Fibrin Structure in patients who have developed VTE in comparison with patients without VTE.
Study NCT03645070 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: multipolar and self expandable thermometer
Description: Will be evaluated if a multipolar and self expandable thermometer is superior to no probe or to single probe thermometer at prevention of esophageal thermal injury.
Study NCT03645070 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Single probe thermometer
Description: Will be evaluated if a single probe thermometer is superior to a multipolar and self expandable thermometer or to no probe thermometer at prevention of esophageal thermal injury
Study NCT02789111 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Alvimopan
Description: Alviimopan 12 mg twice daily up to 15 doses
Study NCT02789111 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo twice daily up to 15 doses
Study NCT04070456 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Tablet-based SDH tool
Description: A tablet-based SDH tool, which integrates responses into the EpicCare electronic health record (EHR).
Study NCT02024828 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Early/Slow
Study NCT02024828 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Early/Fast
Study NCT02024828 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Late/Slow
Study NCT02024828 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Late/Fast
Study NCT00533520 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ranibizumab
Description: Arm A: 0.5 mg ranibizumab on day 0 with retreatment based on defined criteria not to occur sooner than every 28 days Arm B: 1.0 mg ranibizumab on day 0 with retreatment based on defined criteria not to occur sooner than every 28 days Third Arm 2.0mg Arm with retreatment based on defined criteria not to occur sooner than every 28 days
Study NCT01284595 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [14C] AZD8931
Description: Single 160 mg oral dose administered on Day 1
Study NCT01199601 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Concentrated postpartum counseling
Description: Intrapartum testing and concentrated postpartum counseling for the female patient from a retrained provider focusing on correct breastfeeding practices, postpartum contraception, and infant vaccination.
Study NCT00209209 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rituximab
Description: antibody
Study NCT00209209 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: antibody
Study NCT00209209 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclophosphamide
Description: chemotherapy
Study NCT00209209 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: chemotherapy
Study NCT00209209 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Doxorubicin
Description: chemotherapy
Study NCT00209209 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vincristine
Description: chemotherapy
Study NCT00209209 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisone
Description: coricosteroide
Study NCT00209209 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: chemotherapy
Study NCT00209209 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Interferon-alpha
Description: cytokine
Study NCT00209209 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: pegylated formula Interferon-alpha 2b
Description: cytokine
Study NCT00209209 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: chemotherapy: R-CHOP
Description: immuno-chemotherapy
Study NCT00209209 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: chemotherapy: R-FC
Description: immuno-chemotherapy
Study NCT00209209 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Interferon maintenance
Description: cytokine
Study NCT00209209 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Rituximab maintenance
Description: antibody
Study NCT02818556 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Restalyne Silk
Study NCT02818556 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Belotero Balance
Study NCT04241250 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EAW+TS (exoskelton and transspinal stimulation)
Description: Three months of exoskeleton training followed by 6 months of transspinal stimulation.
Study NCT01082666 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Continuous control of cuff pressure
Description: Continuous control of cuff pressure using a pneumatic device (Nosten, Leved, France)
Study NCT01823926 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Noninvasive ventilation
Description: Bilevel positive pressure (BiPAP Synchrony, Respironics®, Murrysville, Pennsylvania, USA) was applied through face mask (Comfort Full 2, Respironics®, Murrysville, Pennsylvania, USA) attached with straps and pressure adjusted were 12 cmH2O of inspiratory pressure and 5 cmH2O of expiratory pressure at the beginning of the procedure (França et al., 2006).
Study NCT01823926 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Noninvasive ventilation
Description: Bilevel positive pressure (BiPAP Synchrony, Respironics®, Murrysville, Pennsylvania, USA) was applied through face mask (Comfort Full 2, Respironics®, Murrysville, Pennsylvania, USA) attached with straps and pressure adjusted were 12 cmH2O of inspiratory pressure and 5 cmH2O of expiratory pressure at the beginning of the procedure (França et al., 2006).
Study NCT01823926 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Jet nebulizer
Description: Both nebulizers were charged with 2.5 mg of salbutamol and 0.25 mg of ipratropium bromide and 3 mL of saline solution was added to complete 3 Ml. JN (Mist yMax, Air Life, Yorba Linda, USA) was positioned in the circuit using a T piece, particle size generation in a 5 µm range (according to the manufacturer information) and flow oxygen tritated at 8 L/min.
Study NCT01082666 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Manual control of cuff pressure
Description: Manual control of cuff pressure is a routine practice in ICU patients
Study NCT02429128 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: 14 weeks exercise training
Study NCT02429128 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: 14 weeks exercise training
Study NCT01823926 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: The vibrating mesh nebulizer (VMN)
Description: Both nebulizers were charged with 2.5 mg of salbutamol and 0.25 mg of ipratropium bromide and 3 mL of saline solution was added to complete 3 Ml. VMN (Aeroneb Solo, Galway, Ireland) was positioned in the mask using an elbow (Elbow Kit, Respironics®, Murrysville, Pennsylvania, USA), particle size generation in a 1 µm and connected to electrical energy.
Study NCT05553808 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Docetaxel
Description: Docetaxel was administered as IV infusion.
Study NCT03581344 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Repetition of Re-staging
Description: Second clinical and instrumental re-evaluation after 11-12 weeks and then surgery 13-16 weeks after the end of chemoradiotherapy if major or complete response at 7-8 weeks
Study NCT02873481 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Centering Pregnancy Care plus Yoga (CPC+Y)
Description: Gentle prenatal yoga for 30 minutes at the end of the Centering Pregnancy Care session
Study NCT04364165 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Standard invitation to free HIV testing at mobile clinic
Description: Participants receive standard invitation to same day HIV testing at mobile clinic.
Study NCT04364165 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: U=U messaging and invitation to free HIV testing at mobile clinic
Description: Participants receive messaging about being undetectable equals untransmittable (U=U) and invitation to same day HIV testing at mobile clinic.
Study NCT01696474 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib
Study NCT02521948 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MANTA Vascular Closure Device
Description: The MANTA device developed by Essential Medical, Inc., is a vascular closure device (VCD) intended for use in catheterization laboratories following percutaneous cardiac or peripheral procedures that use the retrograde common femoral artery access route for large bore (10-18F) interventional devices.
Study NCT02742779 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GDC-0310
Description: Participants will receive single or multiple ascending doses of GDC-0310 orally in fasted or fed state.
Study NCT02742779 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will receive placebo matched to GDC-0310 as single or multiple oral dose in fasted or fed state.
Study NCT04022057 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ropivacaine injection
Description: Local anesthetic injection
Study NCT04022057 — intervention group
Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Dextrose 5
Description: Sham Injection
Study NCT05553808 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Docetaxel was administered as IV infusion.
Study NCT05553808 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Feladilimab
Description: Feladilimab was administered as IV infusion.
Study NCT03726034 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Life Story Book
Description: The protocol of life story book creation is validated in Hong Kong. The life story book would contain two elements: (1) the development of the older adults over the course of his/her lifetime (i.e. from childhood to old age); and (2) the psychosocial development and ways of life of the older adults (e.g. education, marriage, career, and hobbies). The product of the intervention will be a written story with pictures or other memorabilia that are meaningful to the older adults. There is no limitation on the number of words, pages, and pictures. Four to six 60-minute scheduled sessions will be needed for the older adult and the live-in migrant caregivers to discuss and produce the lifestory book at home.
Study NCT03726034 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Self-selected social activities
Description: To control the possible social interaction effects on the dyadic relationship and wellbeing, the caregivers of the control group will conduct self-selected social activities with older adult at home individually for four times weekly.
Study NCT02086357 — intervention group
Intervention type: PROCEDURE
Intervention: SWUE
Study NCT01299246 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Michigan Neuropathy Screening Instrument
Description: Peripheral neurological assessment was carried out using MNSI. The diabetes nurse educators assessed five parameters on both feet and counted the total points, ranging from 0 to10: (1) Appearance of feet; if abnormal, then inspection of lower limbs for deformities was carried out; (2) Identification of foot ulceration; (3) Vibration perception of the big toe; (4) Ankle reflexes; (5) touch-pressure sensation test with a 10 g Semmes-Weinstein monofilament.
Study NCT01556438 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tabalumab
Description: Administered IV
Study NCT01556438 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib IV
Description: Administered IV
Study NCT01556438 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib SC
Description: Administered SC
Study NCT01556438 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Administered orally
Study NCT01597544 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: CISC instruction pre-operatively
Description: Patients allocated to the pre-operative CISC teaching group will be taught how to perform CISC by one of urogynecology nurses working at the Women's Health Care Centre. Patients will be allowed to practice until they feel comfortable with the technique. This should take approximately 30 minutes. The session will take place on the day of their pre-operative medical appointment (PAF), which normally occurs less than a month before the surgery. If a patient is not seen in PAF or is seen more than a month before her surgery, a separate appointment for CISC teaching during the month preceding the surgery will be organized. Post-operatively, a nurse from the hospital gynecology unit will review the technique to make sure the patient is still comfortable with performing CISC.
Study NCT01494402 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: D961S
Description: Oral gelatine capsule
Study NCT01494402 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Esomeprazole
Description: Oral HPMC capsule
Study NCT01494402 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Buffered acetylsalicylic acid
Description: Tablet
Study NCT00854451 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: omeprazole plus amoxicillin
Study NCT04094454 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: special tampon with a diameter of 28mm
Description: patients will use a special tampon with extended vaginal dilatation (diameter 28mm) during radiotherapy
Study NCT04094454 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: standard tampon with a diameter of 12-13mm
Description: patients in Arm B will use a normal commercially available tampon (diameter 12-13mm) during radiotherapy
Study NCT02734212 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Ending Self Stigma for PTSD
Description: Ending Self Stigma for PTSD (ESS-P) is a 9-session small-group (6-8 persons) course designed to help individuals with PTSD develop skills to effectively cope with stigma and minimize the internalization of stigmatizing beliefs and stereotypes. Sessions combine in-class lecture, discussion of relevance to group members' personal experiences, review and practice of strategies and skills, and group sharing, support, and problem-solving. Each session is designed to focus on a specific strategy for addressing self-stigma.